Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Per-Ola Freskgard"'
Autor:
Christophe Schweitzer, Christoph Patsch, Joerg Hoernschemeyer, Eric A. Kitas, Eike Hoffmann, Jens Niewoehner, Nadine Ruderisch, Karlheinz Baumann, Sylwia Huber, Per-Ola Freskgard, Hansruedi Loetscher, Jörg Benz, Achim Gärtner, Arne C. Rufer, Carlo Cusulin, Tina Bülau, Andreas Kuglstatter, Wolfgang Guba, Daniel Schlatter
Publikováno v:
EBioMedicine
EBioMedicine, Vol 24, Iss C, Pp 76-92 (2017)
EBioMedicine, Vol 24, Iss C, Pp 76-92 (2017)
Therapeutic approaches to fight Alzheimer's disease include anti-Amyloidβ (Aβ) antibodies and secretase inhibitors. However, the blood-brain barrier (BBB) limits the brain exposure of biologics and the chemical space for small molecules to be BBB p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84ad5bf832352c9060ecd331ea0b6c7b
https://doi.org/10.1016/j.ebiom.2017.09.004
https://doi.org/10.1016/j.ebiom.2017.09.004
Publikováno v:
PLoS ONE, Vol 15, Iss 3, p e0229850 (2020)
PLoS ONE
PLoS ONE
Reducing Amyloid β (Aβ) in the brain is of fundamental importance for advancing the therapeutics for Alzheimer`s disease. The endogenous metallopeptidase neprilysin (NEP) has been identified as one of the key Aβ-degrading enzymes. Delivery of NEP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3ad5bb6277c8deb5134a91b463aab3b
https://doi.org/10.1371/journal.pone.0229850
https://doi.org/10.1371/journal.pone.0229850
Autor:
Felix C. Weber, Claas A. Meyer, Martin Ebeling, Per-Ola Freskgard, Antonio Iglesias, Michael Reth, Peter Bruenker, Thomas Singer, Sonja Schlicht, Daniel Breustedt, Jens Niewoehner
Publikováno v:
Pharmaceutical Research
Purpose Administration of therapeutic monoclonal antibodies (mAbs) is frequently accompanied by severe first infusion reactions (FIR). The mechanism driving FIR is still unclear. This study aimed to investigate the cellular and molecular mechanisms c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57880e70f6e84db495ed9dd8a8a71622
https://pubmed.ncbi.nlm.nih.gov/29951887
https://pubmed.ncbi.nlm.nih.gov/29951887
Autor:
Wei He, Curtis R. Warren, Wei Pan, Michael Prummer, Leonard I. Zon, Friedrich G. Kapp, Ravi Jagasia, Robert E. Gerszten, Martin Graf, Ulrich Certa, Isaac Adatto, Dorothee Kling, Klaus Christensen, Elliot L. Chaikof, Roland Jakob-Roetne, Chad A. Cowan, Eduard Urich, Ludivine Challet-Meylan, Stephanie J. Grainger, Paul L. Huang, Per-Ola Freskgard, Yulei Xia, Tobias Heckel, Mary H.C. Florido, Christoph Patsch, Lin Sun, John F. O'Sullivan, Eva C. Thoma, Roberto Iacone
Publikováno v:
Nature cell biology
Nature Cell Biology
Nature Cell Biology
The use of human pluripotent stem cells for in vitro disease modelling and clinical applications requires protocols that convert these cells into relevant adult cell types. Here, we report the rapid and efficient differentiation of human pluripotent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fd592cca040a21a696e804399c8e712
https://doi.org/10.1038/ncb3205
https://doi.org/10.1038/ncb3205
Autor:
Antonio Iglesias, Jens Niewoehner, Jens Fischer, Bernd Bohrmann, Alexander Bujotzek, Joerg Moelleken, Felix C. Weber, Thomas Singer, Georg Tiefenthaler, Martin Ebeling, Kevin Brady, Petra Rueger, Per-Ola Freskgard
Publikováno v:
Cell Reports, Vol 22, Iss 1, Pp 149-162 (2018)
Summary: Receptors show promise for the transport of monoclonal antibodies (mAbs) across the blood-brain barrier. However, safety liabilities associated with peripheral receptor binding and Fc effector function have been reported. We present the Brai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8f91add0e98b7fb6fd2eb88b6b6b260
https://pubmed.ncbi.nlm.nih.gov/29298417
https://pubmed.ncbi.nlm.nih.gov/29298417
Autor:
Christof Kugler, Hansruedi Loetscher, Per-Ola Freskgard, Basil Kuennecke, Michelle Ammann, Fiona Grüninger, Laurence Ozmen, Roberto Villaseñor, Ludovic Collin
Publikováno v:
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. 37(12)
The blood–brain barrier (BBB) regulates differing needs of the various brain regions by controlling transport of blood-borne components from the neurovascular circulation into the brain parenchyma. The mechanisms underlying region-specific transpor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a3c49fb66c441b46fd8733e26118026
https://pubmed.ncbi.nlm.nih.gov/29098547
https://pubmed.ncbi.nlm.nih.gov/29098547
Autor:
Hansruedi Loetscher, Annika Keller, Laurence Ozmen, Fiona Grüninger, Roberto Villaseñor, Christer Betsholtz, Ludovic Collin, Per-Ola Freskgard, Nadia Messaddeq
Publikováno v:
Scientific Reports
Scientific Reports, Nature Publishing Group, 2016, 6, ⟨10.1038/srep25658⟩
Scientific Reports, Nature Publishing Group, 2016, 6, ⟨10.1038/srep25658⟩
The Blood-Brain Barrier (BBB) restricts access of large molecules to the brain. The low endocytic activity of brain endothelial cells (BECs) is believed to limit delivery of immunoglobulins (IgG) to the brain parenchyma. Here, we report that endogeno
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e928e6bd51d8a09b5cb3d2d6effe29aa
http://europepmc.org/articles/PMC4858719
http://europepmc.org/articles/PMC4858719
Publikováno v:
Future Neurology. 9:243-245
Pharma Research & Early Development (pRED), Neuroscience Discovery & Translation Area, F Hoffmann-La Roche, Basel, Switzerland Pharma Research & Early Development (pRED), Large Molecule Research, F Hoffmann-La Roche, Penzberg, Germany *Author for cor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b94ad2b6d9a66cc673e1bd71c5f87f51
https://doi.org/10.2217/fnl.14.15
https://doi.org/10.2217/fnl.14.15
Autor:
Per-Ola Freskgard, Eduard Urich
Publikováno v:
Neuropharmacology. 120
Therapeutic antibodies have essentially been banned from the central nervous system, and are so far limited to use mainly in multiple sclerosis. This is primarily due to the fact that antibody penetration across the blood-brain barrier is very limite
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d05fc1c461a6e3d2cefb06bbd706f9e3
https://pubmed.ncbi.nlm.nih.gov/26972827
https://pubmed.ncbi.nlm.nih.gov/26972827
Autor:
Roland Schmucki, Hansruedi Loetscher, Helmut Jacobsen, Ulrich Certa, Martin Ebeling, Nadine Ruderisch, Eduard Urich, Eric A. Kitas, Christophe Schweitzer, Alessandra Bergadano, Per-Ola Freskgard
Publikováno v:
Scientific Reports
The blood-brain barrier and the blood-cerebrospinal fluid barrier prevent access of biotherapeutics to their targets in the central nervous system and therefore prohibit the effective treatment of neurological disorders. In an attempt to discover nov
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24a6a0f2ebf0ddc82b5e563c5c507a7f
https://doi.org/10.1038/srep14104
https://doi.org/10.1038/srep14104